Summit Wireless Technologies Reports Preliminary 2021 Revenue, Up Over 170% Year-over-Year
January 18 2022 - 07:00AM
Business Wire

- Delivers Record Quarterly Revenue -

Summit Wireless Technologies (NASDAQ: WISA), reported that preliminary revenue for the fourth quarter ended December 31, 2021 is expected to be approximately $2.0 million, bringing the full year 2021 preliminary revenue to $6.5 million.

“Summit’s spatial audio technology and the WiSA Wave program are driving our growth, as Q4 delivered our sixth consecutive quarter of revenue increases and our first quarter of $2.0 million in revenue,” said Brett Moyer, CEO, President, and Chairman of Summit Wireless Technologies. “During the fourth quarter, the Wave attracted nearly 1 million consumers to the websites. Thus, the full year visitor count exceeded 2 million, up over 445% up from 365,800 in 2020. Building WiSA’s technology brand with consumers and the retail channel is accelerating with each visitor to our websites, to WiSA storefronts, and to certified product pages thereby building a strong foundation for launching new technologies this year.”

Preliminary Revenue

Q4 2021 preliminary revenue is expected to be approximately $2,000,000, up over 90% compared to $1,038,000 in Q4 2020, the quarter in which the Wave was introduced and first started to fuel revenue growth.
2021 preliminary revenue is expected to be approximately $6,541,000, up over 170% compared to $2,404,000 in 2020.
Cash Balance

At December 31, 2021, preliminary cash and cash equivalents are expected to be approximately $13.1 million.

Regarding 2022, management expects to continue to build WiSA’s technology brand by expanding the WiSA Wave effort to Europe and China, increase websites visitors to 3 million to 5 million, and launch more products. As part of the Wave initiative, the WiSA Association launched a new website www.wisatechnologies.com, which will serve as the primary site to promote WiSA products and expand category marketing initiatives.

About WiSA, LLC

WiSA® educates, evangelizes, and promotes solutions for spatial audio in the home. Working in collaboration with technology developed by Summit Wireless Technologies, WiSA engages with leading consumer electronics companies, technology providers, retailers, and ecosystem partners to make immersive audio an experience everyone can enjoy. WiSA, LLC - the Wireless Speaker and Audio Association - is a wholly owned subsidiary of Summit Wireless Technologies, Inc. For more information about WiSA, please visit: www.wisatechnologies.com.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is the developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems marketed under the WiSA brand. Summit’s technology delivers immersive audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Headquartered in San Jose, CA, Summit Wireless has sales teams in Taiwan, China, Japan, and Korea. For more information, please visit: www.summitwireless.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified™ speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2022 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.

Safe Harbor Statement

This press release contains forward-looking statements, which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. As a result, readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting Summit Wireless’ business including, current macroeconomic uncertainties associated with the COVID-19 pandemic, our inability to predict or measure supply chain disruptions resulting from the COVID-19 pandemic and other drivers, our ability to predict the timing of design wins entering production and the potential future revenue associated with our design wins; our rate of growth; our ability to predict direct and indirect customer demand for our existing and future products and to secure adequate manufacturing capacity; our ability to hire, retain and motivate employees; the effects of competition, including price competition within our industry segment; technological, regulatory and legal developments that uniquely or disproportionately impact our industry segment; developments in the economy and financial markets and other risks detailed from time to time in Summit Wireless’ filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005466/en/

Kirsten Chapman, LHA Investor Relations, 415-433-3777, wisa@lhai.com

11/14/2021 Quarterly Report - Quarterly Report 09/30/2021
https://www.otcmarkets.com/otcapi/company/financial-report/311174/content

Predictive Oncology Inc. Announces Newest Board Member
April 27 2021 - 08:30AM
GlobeNewswire Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce today their newest Board Member Dr. Christina Jenkins.
Dr. Christina Jenkins is a strategic advisor and venture investor whose expertise spans clinical medicine, venture capital, health systems and health plans. She applies her unique perspective of providers, payers, and consumers to help leaders optimize growth and health outcomes.

Dr. Jenkins is a Venture Partner at Phoenix Venture Partners (PVP), where she co-leads the firm’s seed-stage investment strategy in the healthcare/life sciences vertical. She is focused on hardware-enabled platform companies that are transforming the way we diagnose, monitor, and treat health conditions. She also leads investments for Portfolia’s FemTech and Active Aging and Longevity funds, focusing on evidence-backed digital health and device companies targeting the health of women.

Previously, Dr. Jenkins was the founding CEO of OneCity Health Services, a subsidiary of NYC Health + Hospitals (H+H), where she built a team to 130 people and led a successful $1.2B effort to design and implement technology-enabled care models and accelerate value-based payment (financial risk) readiness for 1M lives.

She is a Board Director for Independence Health Group (parent of Independence Blue Cross and AmeriHealth Caritas), a Board Observer for Madorra, and an advisory board member of multiple value-generating healthcare companies.

"We are very fortunate to have Dr. Jenkins join our Board of Directors. As a medical doctor she brings additional insight and perspectives to our team. She has participated and led companies to success in health services and will have an immediate impact at Predictive Oncology and will strengthen our strategic positioning in the market," said Chief Executive Officer J. Melville Engle.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net

WiSA Association Certifies LG’s 2021 OLED and NanoCell TVs to be WiSA Ready
April 05 2021 - 07:00AM
Business Wire
WiSA leads consumer electronics industry with integration of new WiSA Ready™ LG models

WiSA® LLC, the Wireless Speaker and Audio Association comprised of over 70 leading consumer electronics brands and founded by Summit Wireless Technologies (NASDAQ: WISA), today announced WiSA Ready™ certification of LG’s 2021 OLED and NanoCell TVs further expanding its lineup of existing WiSA Ready™ TV models.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005071/en/

WiSA Ready™ LG 2021 OLED TV (Photo: Business Wire)
WiSA Ready™ LG 2021 OLED TV (Photo: Business Wire)

LG Electronics continues to lead numerous WiSA member brands, including Hisense, Skyworth, Bang & Olufsen and more who have integrated with WiSA technology for their premium TVs. Whether it be high-quality TVs or speaker systems, LG brings unmatched entertainment straight to any living room and remains a leader in integrating immersive audio connectivity. All WiSA Ready™ LG TVs easily connect to WiSA USB Transmitters, allowing seamless audio and control communication with all WiSA Certified™ speakers.

“LG has consistently led the way with cutting edge TVs that elevate home entertainment,” said Tim Alessi, LG USA’s senior director of home entertainment product marketing. “We were the first company to offer WiSA compatibility built-into our TVs and are pleased to continue to offer this capability in our new 2021 OLED and NanoCell models to allow consumers to connect wirelessly with their audio systems to create the most immersive viewing experience.”

These new LG TV models are designed to sync perfectly with WiSA technology, ensuring seamless speaker synchronization, high-fidelity sound and low-latency through a wide-ranging selection of WiSA Certified™ speakers from well-known brands like Klipsch, Enclave Audio and Axiim, among many others.

“We’re excited to see LG Electronics continue to produce TVs with amazing picture quality and additional industry-leading features to enhance cinema-like viewing experiences in the home,” said Tony Ostrom, WiSA President. “The 2021 OLED and NanoCell models are extraordinary examples of what sets our Association’s members apart from other CE brands.”

All WiSA Ready™ and WiSA Certified™ components work together to deliver multi-channel, wireless audio capabilities creating concert quality sound for the enjoyment of movies, sports, gaming, streaming and more. The syncing of LG TVs with any WiSA Certified™ speaker takes only minutes for setup and is controlled with the LG TV remote right from the TV’s user interface.

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also ensures robust, high definition, multi-channel, low latency audio while eliminating the complicated set-up of traditional audio systems. For more information about WiSA, please visit: www.wisaassociation.org.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information about Summit Wireless Technologies, Inc., please visit: www.summitwireless.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified™ speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2021 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005071/en/

Sarah Cox, Dittoe PR for WiSA, 765.546.1036, sarah@dittoepr.com
Keith Washo, WiSA Association, 984.349.272, kwasho@wisaassociation.org

Annual Report Date End Period 12/31/2020
https://backend.otcmarkets.com/otcapi/company/financial-report/276008/content

Predictive Oncology Inc. Announces New CEO
March 23 2021 - 08:30AM
GlobeNewswire Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J. Melville (“Mel”) Engle as Chief Executive Officer of the company.
In addition to being named CEO, Mr. Engle will retain his role of Chairman of the Board. Mr. Engle joined POAI’s Board of Directors in October, 2016 and was appointed Chairman of the Board in January, 2020.

Mr. Engle has over 20 years’ experience in leadership roles in both the biotechnology and healthcare industries. He has extensive experience in turning companies around and driving sales. He has served in top level capacities e.g., President, CEO, Director, Chairman of the Board, CFO, Regional Director (North America), Managing Director (Canada) and Senior VP of Sales (US) and has launched hundreds of products. Mr. Engle replaces Dr. Carl I. Schwartz, who has retired.

Mr. Engle was previously the Chief Executive Officer of Engle Strategic Solutions (www.englestrategicsolutions.com) where his practice specialized in consulting and coaching for CEOs and business owners. Prior to starting his consulting practice in 2012, Mr. Engle was CEO, Chief Executive Officer of Thermogenesis, a Nasdaq-listed company. Thermogenesis designed, developed and sold medical devices that enabled the practice of regenerative medicine.

In 2002, Mr. Engle was recruited by Merck KGaA to serve as President and CEO of Dey L.P, a division of Merck. Dey L.P, was a pharmaceutical company focused on the development and commercialization of products for respiratory, allergy and other breathing disorders. Mr. Engle was instrumental in transforming Dey's company strategy from 90% commodity generics to 90% branded products, resulting in consecutive years of significant growth. During Mr. Engle's tenure, sales increased from $250 million to over $600 million. Dey L.P. was a cornerstone company with the Merck Generics Group (MGG), a division of Merck KGaA. Mr. Engle was also Regional Director, North America for MGG, and led all of their North American businesses, specifically Dey L.P., Genpharm, Inc. (Canada) and Genpharm, L.P. (U.S.) with total sales of $800 million and 1,200 employees. From 1980 to 1994, Mr. Engle was a senior executive with Allergan, Inc. Allergan marketed branded eye care pharmaceuticals, surgical and diagnostic equipment, dermatological products, and Botox. Mr. Engle played key roles within the organization as CFO, Managing Director, Canada (located in Toronto), Senior Vice President, Latin America/Canada, and Senior Vice President, U.S. Sales.

"We are excited to bring in Mr. Engle’s significant experience in key facets sought by emerging biotech companies. His leadership and expertise in the biopharmaceutical industry, as well as his knowledge of efficient execution strategies will be invaluable," said Bob Myers, Chief Financial Officer.

“I believe that Predictive Oncology is positioned for success and I look forward to working with our team to achieve its strategic short- and long-term objectives. I am excited about the prospects of making a positive impact in enhancing the value for our stakeholders,” said Mr. Engle.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in cell culture media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
kpinder@landoncapital.net

WiSA Member Foxconn Demos Sharp 120-Inch 8K TV with WiSA SoundSend & Wireless Audio Speaker System at Appliance & Electronics...
March 23 2021 - 07:00AM
Business Wire
Foxconn will demo its new, huge 120-inch 8K TV connected to the award-winning WiSA SoundSend and Platin Monaco 5.1 speaker system at this week’s industry event in Shanghai

WiSA® LLC, founded by Summit Wireless Technologies (NASDAQ: WISA), today announced that Association member Foxconn will showcase WiSA technology in the form of the award-winning WiSA SoundSend and 5.1 WiSA Certified speaker system around its big, bold and beautiful 120-inch 8K TV at the Appliance & Electronics World Expo (AWE) in Shanghai, China, March 23-25.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005249/en/

Foxconn Sharp 120-Inch 8K TV (Photo: Business Wire)
Foxconn Sharp 120-Inch 8K TV (Photo: Business Wire)

The Foxconn booth at AWE will highlight immersive home entertainment audio and video experiences that are possible when a breathtakingly large and stunning screen is combined with a Tuned by THX™ 5.1 audio system that can be set up in minutes. The Sharp-branded 8K TV utilizes ARC/eARC and CEC to connect and communicate perfectly with the WiSA SoundSend, while mobile applications for iOS and Android make advanced tuning a simple process.

“We are thrilled to partner with Foxconn and Sharp at AWE to show what is possible when stunning, large-scale video and immersive audio are combined,” stated Tony Ostrom, WiSA President. “As TVs get bigger and more capable of accessing stunning, highly-produced content, we strive to enable the home entertainment experience to include amazing audio that is both easy to use and readily available. This combined demo at AWE is a great example of that goal being achieved.”

AWE is Asia’s largest consumer electronics show and offers top-tier products, technology exchange platforms, and CE brands from around the world. After being put on hold in 2020 due to the pandemic, this year’s expo will adhere to health and safety regulations to ensure a successful event.

For more information on the Association and its WiSA Ready and WiSA Certified products, visit www.wisaassociation.org.

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also ensures robust, high definition, multi-channel, low latency audio while eliminating the complicated set-up of traditional audio systems. For more information about WiSA, please visit: www.wisaassociation.org.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information about Summit Wireless Technologies, Inc., please visit: www.summitwireless.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified™ speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2021 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005249/en/

Sarah Cox, Dittoe PR for WiSA, 765.546.1036, sarah@dittoepr.com
Keith Washo, WiSA Association, 984.349.272, kwasho@wisaassociation.org

AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COV...
March 22 2021 - 08:45AM
GlobeNewswire Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a protocol amendment to Roswell Park’s ongoing Phase 1/2a study evaluating the two-drug combination of AIM’s Ampligen and interferon alpha-2b as a potential early-onset treatment for patients with cancer and mild-to-moderate COVID-19.
The IRB-approved amendment calls for randomization of an additional twenty patients. Ten of these patients will receive a single dose of Ampligen, but no interferon treatment, and the other ten will receive best available care only. Ampligen alone has a generally well-tolerated safety profile with lower risk of adverse events than is generally expected with interferon therapy.

"We are excited to see Ampligen tested not only as part of an antiviral treatment combination for COVID-19 among cancer patients, but also as a possible standalone therapy for this terrible virus,” said AIM CEO Thomas K. Equels. “An early-onset treatment is especially critical for cancer patients, who face significantly increased risk of severe symptoms or death."

AIM previously announced in November 2020 that the first patient had been enrolled and received treatment in Roswell Park’s study. Funding for the clinical trial is provided, in part, through grants from the National Cancer Institute and AIM, as well as institutional support from Roswell Park.

Full details about this trial under way at Roswell Park, led by co-Principal Investigators Drs. Brahm Segal and Pawel Kalinski, are available at ClinicalTrials.gov.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. In this regard, the Roswell Park Clinical Trial Agreement is one of the first steps and no assurance can be given as to whether the Roswell Park trial and/or subsequent trials will prove successful. Some of the world’s largest pharmaceutical companies are racing to find a treatment for COVID-19. Even if Ampligen proves effective in combating the virus, no assurance can be given that our actions toward proving this will be given first priority or that, even if Ampligen proves effective, another treatment that eventually proves effective will not make our efforts ultimately unproductive. No assurance can be given that future studies will not result in findings that are different from those reported in studies the Company is relying on. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks. With regard to the Company’s activities with Ampligen generally, no assurance can be given as to whether current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Any forward-looking statements set forth herein speak only as of the date of this press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

Nice News. But still totally under the radar.

Hisense TVs Certified WiSA Ready™, WiSA’s Interoperability Standard Becoming Must-Have Feature for Smart TVs
March 18 2021 - 07:00AM
Business Wire
Leading consumer electronics brand Hisense drives consumer value with its WiSA Ready™ smart TV product line

WiSA® LLC, founded by Summit Wireless Technologies (NASDAQ: WISA), today announced a global collaboration with rapidly growing TV brand Hisense in which the brand’s premier 2021 TV models have been certified WiSA Ready™. This allows for a quick and simple connection to all WiSA USB transmitters and WiSA Certified™ Speakers to create amazing and immersive home cinema systems. Hisense joins numerous WiSA member brands, including LG, Skyworth, Bang & Olufsen, and more who are implementing integrated wireless technology into meaningful product lines and launches.

“Hisense is proud to be pushing the performance envelopes of video and audio with the launch of our 2021 North America TV models,” said David Gold, President of Hisense America. “WiSA continues to lead the emerging wireless audio category and we are proud to achieve WiSA Ready Certification and deliver solutions that will provide amazing, convenient, and immersive entertainment experiences for millions of consumers.”

Hisense is the fifth leading TV brand in the U.S. and the fastest growing among the top five TV brands in the U.S., by units*. The company’s continued growth and rapid rise in rankings is a testament to its success in the U.S. Their award-winning product lineup was well-received in 2020 and Hisense is continuing to build on its high-performing and high-quality products by bringing even more options to the market in 2021 for consumers to have a premium viewing experience.

“We are very excited to announce the WiSA Ready Certification of these amazing TVs from Hisense,” said Tony Ostrom, President of WiSA. “As the smart TV continues to solidify itself as the center of the home entertainment experience, it is critical for these multifunctional devices to own the front end of great audio performances. WiSA Ready TVs can be seamlessly connected to transmitters and speakers to create immersive sound with direct control from the TV. This is a huge step forward in simplifying the pursuit of bringing outstanding cinema quality entertainment into the home.”

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also ensures robust, high definition, multi-channel, low latency audio while eliminating the complicated set-up of traditional audio systems. For more information about WiSA, please visit: www.wisaassociation.org.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information about Summit Wireless Technologies, Inc., please visit: www.summitwireless.com.

About Hisense USA Corporation and Hisense Company, LTD.

Hisense USA Corporation is a subsidiary of Hisense Company, Ltd., established in 1969 and headquartered in Qingdao, China. Hisense USA Corporation offers an innovative range of technology products that disrupt the consumer electronics industry, challenge the competition and provide significant value to consumers. To learn more contact Max Borges Agency for Hisense at hisense@maxborgesagency.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2021 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005031/en/

Sarah Cox, Dittoe PR for WiSA, 765.546.1036, sarah@dittoepr.com
Keith Washo, WiSA Association, 984.349.272, kwasho@wisaassociation.org
Max Borges Agency for Hisense hisense@maxborgesagency.com

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule
March 16 2021 - 08:00AM
GlobeNewswire Inc.

Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition and diagnostics company that develops clinically supported nutritional supplements, medical foods, and medical devices, announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market pursuant to Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). On March 15, 2021, Guardion received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC (“Nasdaq”) stating that because Guardion’s Company’s common stock (the “Common Stock”) had a closing bid price at or above $1.00 per share for a minimum of ten (10) consecutive trading days, its Common Stock had regained compliance with Nasdaq’s Minimum Bid Price Rule.
On September 20, 2019, the Company received notice from Nasdaq indicating that, based upon the closing bid price of the Common Stock, the Company no longer satisfied the Minimum Bid Price Rule. The Company was afforded 180 calendar days, or until March 18, 2020, to regain compliance with the Minimum Bid Price Rule. Thereafter, the Company was afforded a second 180 calendar day compliance period (which 180-day period was extended due to circumstances related to COVID-19), or until November 30, 2020, to regain compliance with the Minimum Bid Price Rule.

The Company was unable to regain compliance with the Minimum Bid Price Rule by November 30, 2020. Accordingly, on December 1, 2020, the Company received a letter from Nasdaq notifying it that its Common Stock would be subject to delisting from Nasdaq unless the Company timely requested a hearing before a Nasdaq Listing Qualifications Panel (the “Panel”). The Company timely requested the hearing.

Following the hearing, on January 26, 2021, the Company received written notification that the Panel had granted the Company an extension for continued listing through March 15, 2021. As referenced above, Nasdaq determined that the Company complied with the Panel’s decision and has regained compliance. Accordingly, Nasdaq has closed the compliance review.

About Guardion Health Sciences

Guardion Health Sciences, Inc. (NASDAQ: GHSI), is a clinical nutrition and diagnostics company. Guardion offers a portfolio of science-based, clinically supported nutrition, medical foods, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion’s commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion’s growing position within the eye care industry and the clinical nutrition marketplace. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statement Disclaimer

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but are not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the integration of a new management team, the impact of the COVID-19 pandemic on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s listing requirements. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
CORE IR
Scott Arnold
516-222-2560
scotta@coreir.com

Media Relations Contact:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

Summit Wireless Technologies Reports Record Fourth Quarter 2020 Revenue and Gross Margin
March 12 2021 - 06:30AM
Business Wire
Q4 2020 Revenue Increased 141% Year-over-Year to a Record $1.0 Million; Operational Execution Drives Gross Margin Improvement to 24% from 17% in Q3 2020

Summit Wireless Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems, provided an update for the fourth quarter ended December 31, 2020.

Q4 2020 Financial Highlights:

Revenue increased 141% to over $1.0 million, compared to $430,000 in the fourth quarter of 2019.
Gross margin expanded to 24%, compared to 17% in the third quarter of 2020.
Cash and cash equivalents of $7.4 million at December 31, 2020, compared to $298,000 at December 31, 2019.
Q1 2021 Financial Guidance:

Revenue expected to increase at least 100% compared to the first quarter of 2020.
Gross margin expected to be in mid-20s range.
Cash and cash equivalents expected to range from $9 million to $10 million at March 31, 2021.
“With our WiSA Wave marketing program driving record revenue in the fourth quarter of 2020, we entered 2021 with substantial momentum,” said Brett Moyer, CEO of Summit Wireless. “Since launching the marketing initiative, the number of consumers driven to the WiSA Association, brand and retailer websites grew significantly, enabling us to educate and connect with those looking for a simple, immersive home audio experience. The WiSA branded SoundSend multichannel wireless audio transmitter was recognized for its innovation at CES 2021 by the Consumer Technology Association. Today, WiSA supports over 70 consumer electronics brands as an industry standard and in 2021 over 25 brands will ship Summit Wireless technology.”

“We expect the explosive growth in consumer traffic at the WiSA Association and related websites to continue surpassing 1 million visitors in 2021, which will be a direct catalyst for our long-term operating performance. As WiSA members launch more products into the market, we anticipate capturing market share by providing consumers with our state-of-the-art audio technology across a variety of price points. I thank our industry partners, employees, and shareholders for their support thus far, and look forward to what I expect to be a breakout year for Summit Wireless,” concluded Moyer.

On today’s conference call, management will discuss expanding the WiSA Association to a consumer facing platform to drive retail sales.

Recent Business Highlights:

WiSA Wave marketing program drove record consumer traffic to over 185,000 visitors in the fourth quarter of 2020, which is expected to increase to over 1 million customers in 2021.
WiSA Association membership grew to over 70 brands in 2020.
Over 25 brands are shipping Summit Wireless technology in 2021.
LG Electronics WiSA Ready™ 4K UHD Smart Projector is now available in the United States.
Discovery, Summit’s first low-cost IoT module targeted at high volume, entry-level systems, launched at CES 2021.
WiSA SoundSend won three awards: CES 2021 Innovation Award Honoree, Dealerscope !MPACT Winner 2021 and Twice 2021 Picks Awards Winner.
Summit Wireless Investor Update Conference Call

Summit Wireless will host a conference call at 8:00 a.m. PT / 11:00 a.m. ET on Friday, March 12, 2021 to provide a business update. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 877-423-9813 or 201-689-8573 and referencing code 13716790 approximately 10 minutes prior to the start time and view accompanying slides at ir.summitwireless.com/events. To bypass the operator and receive a call rather than dialing in, please use the following link approximately 15 minutes prior to the call. A live webcast of the call and accompanying slide presentation will be on the investor relations section of the company’s website at ir.summitwireless.com and available for approximately one year. An audio archive can be accessed for one week by dialing 844-512-2921 or 412-317-6671 and entering conference ID 13716790.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information, please visit: www.summitwireless.com.

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also combines robust, high definition, multi-channel, low latency surround sound with the simple setup of a soundbar. For more information about WiSA, please visit: www.wisaassociation.org.

© 2021 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA, WiSA Ready, and WiSA Certified are trademarks, or certification marks of WiSA LLC.

Safe Harbor Statement

This press release contains forward-looking statements, which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. As a result, readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting Summit Wireless’ business including, current macroeconomic uncertainties associated with the COVID-19 pandemic, our ability to predict the timing of design wins entering production and the potential future revenue associated with our design wins; our rate of growth; our ability to predict customer demand for our existing and future products and to secure adequate manufacturing capacity; consumer demand conditions affecting our customer’s end markets; our ability to hire, retain and motivate employees; the effects of competition, including price competition; technological, regulatory and legal developments; developments in the economy and financial markets and other risks detailed from time to time in Summit Wireless’ filings with the Securities and Exchange Commission.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005107/en/

Kirsten Chapman, LHA Investor Relations, 415.433.3777, summit@lhai.com

WiSA Ready™ 4K UHD Smart Projector from LG Electronics Now Available in United States
March 12 2021 - 06:00AM
Business Wire
First-ever WiSA Ready laser projector takes wireless home cinema experience to the next level

WiSA® LLC, founded by Summit Wireless Technologies (NASDAQ: WISA), today announced that Association member LG Electronics’ AU810PB 4K UHD Smart Dual Laser CineBeam Projector, notably the first WiSA Ready™ projector to be introduced to the market, is now available to custom installers and consumers for $3,999 US MSRP via authorized LG dealers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005027/en/

(Photo: Business Wire)
(Photo: Business Wire)

Being the first of its kind with WiSA Ready capabilities, LG’s CineBeam model can easily connect to WiSA USB Transmitters, allowing seamless wireless audio and control communication with all WiSA Certified™speakers. In addition to its wireless audio capabilities, the projector boasts a wide range of projection size flexibility, offering a compact 40-inch projection size all the way to a 300-inch projection. These options allow any user to easily watch a small screen picture in a bedroom or experience larger theater viewing.

“As the latest innovation in LG's popular high-resolution projector lineup, this CineBeam model offers features and technologies that make it the perfect choice for movie lovers who are entertaining at home, said Tim Alessi, LG USA’s senior director of home entertainment product marketing. “Thanks to its large screen and WiSA Ready capabilities, the LG CineBeam AU810PB delivers immersive video and audio experiences to consumers in the comfort of their own homes including access to many of the most popular streaming sites through LG’s webOS platform.”

“It’s exciting to see LG continue to create ground-breaking products that are transforming the home entertainment experience and the CineBeam 4K UHD projector (model AU810PB) is a hallmark example,” said Tony Ostrom, President of WiSA. “We are thrilled the first-ever WiSA Ready projector is now available to complete and perfect a true movie-going experience in the home when coupled with WiSA Certified speakers from brands like Klipsch, Bang & Olufsen, Harman, System Audio and many others. It’s an exciting time for the consumer electronics industry and we are grateful to work with members like LG who prioritize continued innovation.”

For more information on the Association and its WiSA Ready and WiSA Certified products, visit www.wisaassociation.org.

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also ensures robust, high definition, multi-channel, low latency audio while eliminating the complicated set-up of traditional audio systems. For more information about WiSA, please visit: www.wisaassociation.org.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information about Summit Wireless Technologies, Inc., please visit: www.summitwireless.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2020 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005027/en/

Sarah Cox, Dittoe PR for WiSA, 765.546.1036, sarah@dittoepr.com
Keith Washo, WiSA Association, 984.349.272, kwasho@wisaassociation.org

The volume has been so low and so few eyes on it over the years I havent ever loaded heavy but have nailed it several time below .10 and unloading above .20. Best so far was in at .04.
If we ever see real volume QMCI could be a real long term winner.

Platin Audio Debuts Sleek and Powerful New Product Line for Home Cinema Sound
March 11 2021 - 07:00AM
Business Wire
Worldwide WiSA organization welcomes another new Smart Surround Sound System utilizing the WiSA SoundSend Wireless Audio Transmitter

Following the 2020-21 success of the Platin Monaco 5.1 wireless surround sound system, Platin Audio is announcing an additional home cinema product line – The Platin Milan 5.1.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005115/en/

Platin Milan 5.1 (Photo: Business Wire)
Platin Milan 5.1 (Photo: Business Wire)

Platin Milan 5.1 combines fashion, function and affordability together into a totally immersive, 360-degree sensory experience. Featuring WiSA Certified™, compact and unobtrusive satellite speakers with a versatile wrap-around acoustic grill cloth, Milan easily blends into any comfortable living space.

Delivered in a single box, the new Milan surround sound system includes a low-profile and powerful subwoofer that is tied together with the other five Milan speakers over a lossless multi-channel network, utilizing the award-winning WiSA SoundSend audio transmitter. With SoundSend, both Milan and Monaco provide pure 24-bit uncompressed audio for a completely wireless entertainment soundscape. Compatible with all Smart TVs with an HDMI arc or eArc port, SoundSend is capable of recognizing newly added speakers, and Dolby Atmos for overhead sounds and effects, either virtually, or physically with overhead speakers, making it possible to upgrade with ease.

“We are excited to see this great system become available and deliver immersive audio performances at a great price point,” said Tony Ostrom, WiSA President. “A key goal at WiSA is to promote amazing home cinema experiences and help facilitate their availability across large spectrums of styles, prices, and performance levels, thus enabling adoption and enjoyment by a massive number of enthusiasts.”

“With three awards so far this year, the WiSA SoundSend audio transmitter, right along with WiSA Ready™ TVs and other WiSA Certified™ speakers and components, continues to raise the bar for simplified set-up and control of high performance home cinema systems,” said Ostrom.

Like Platin Monaco, Platin Milan utilizes the SoundSend mobile application for easy access and control of features like the MyZone, which allows users to create a “sweet spot” for ideal listening.

Platin Milan is available on Amazon today, and directly from Platinaudio.us in April, 2021. Platinaudio.us also includes additional individual speaker components for system upgrades.

About WiSA, LLC

WiSA®, the Wireless Speaker and Audio Association, is a consumer electronics consortium dedicated to creating interoperability standards utilized by leading brands and manufacturers to deliver immersive sound via intelligent devices. WiSA Certified™ components from any member brand can be combined to dramatically increase the enjoyment of movies and video, music, sports, gaming/esports, and more. WiSA also ensures robust, high definition, multi-channel, low latency audio while eliminating the complicated set-up of traditional audio systems. For more information about WiSA, please visit: www.wisaassociation.org.

About Summit Wireless Technologies, Inc.

Summit Wireless Technologies, Inc. (NASDAQ: WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless, formerly named Summit Semiconductor, Inc., is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information about Summit Wireless Technologies, Inc., please visit: www.summitwireless.com.

* WiSA Ready TVs, gaming PCs and console systems are “ready” to transmit audio to WiSA Certified speakers when a WiSA USB Transmitter is plugged in and a user interface is activated through an APP or product design like LG TVs.

© 2020 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc. The WiSA logo, WiSA®, WiSA Ready™, and WiSA Certified™ are trademarks and certification marks of WiSA, LLC. Third-party trade names, trademarks and product names are the intellectual property of their respective owners.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005115/en/

Sarah Cox, Dittoe PR for WiSA, 765.546.1036, sarah@dittoepr.com
Keith Washo, WiSA Association, 984.349.272, kwasho@wisaassociation.org

Thank you.

Extended ugly days. More opt to acquire more for the long term. Here is a reminded of why POAI is a positive investment from stocktwits.
https://predictive-oncology.com/
https://www.nasdaq.com/market-activity/stocks/poai



$POAI

1. 1 year gain =-40%, avg. Gains=400%
2. 3mo gain = +90% the avg gains =500% in sector
3. 1 mo gain=+1%
4. The largest tumor data lake
5. AI platform hooked up.
6. Pilot program nears the end
7. In negotiation with a customer and the milestone requirement for a contarct, $5m min.
8. Duplicable to other pharmas
9. Tumor Genesis: $1_2m gov. Fund is coming
10. Soluble business: coe an astronaut and $2m rev. Possible.
11. Skyline business: a cash cow. $1±m
12. Helomics, rev from clinics can cover mist of their expenses, so it is likely $2+m again
14. $24m cash no debt.
15.rev.2020 $1.2m to $1.5m

With their saydo score 75% to 80%, go figure what kind of the revenue for 2021 would be.

This is consistent with a Redditor post's figure of 7x + revenues against 2020's

https://stocktwits.com/jjsloth/message/299190110

QMCI has been holding well in these horribly red weeks.

Some trading platforms have a max you can purchase before they allow an order to go through. In the small print.
Try a smaller order. I believe you said you wanted 2 mill? Try 999,999.

What did they say?
Was the registered agent but not now, never was, person dosnt know so said never heard of them?



Changed: 02/22/2021 from filing could mean they are no longer. Or are suppose to be.
Ballas Chris or James can act as agent since a business just need to have a person who is authorized and able to sign for or receive docs (summons, being served or other)

Like lots of info here its vague.

Did you contact Legal Corp Services?


Company Info
LEGALINC CORPORATE SERVICES INC. is a Florida Profit Corporation. Company Number assigned to this company is P12000047957. US Federal EIN/TIN number of this company is 45-3566742.

Florida Limited Liability Company

C-Z PRODUCTS LLC

Filing Information
Document Number
L17000229341
FEI/EIN Number
N/A
Date Filed
11/06/2017
State
FL
Status
ACTIVE
Last Event
REINSTATEMENT
Event Date Filed
02/22/2021
Principal Address
3411 Skysail Pl
Tampa, FL 33607

Changed: 02/22/2021
Mailing Address
3411 Skysail Pl
Tampa, FL 33607

Changed: 02/22/2021
Registered Agent Name & Address
LEGALINC CORPORATE SERVICES, INC.
5237 SUMMERLIN COMMONS
SUITE 400
FORT MYERS, FL 33907

Name Changed: 02/22/2021

Address Changed: 12/04/2017
Authorized Person(s) Detail
Name & Address

Title AMBR

BALLAS, CHRISTOPHER
3450 PALENCIA DR APT 1311
TAMPA, FL 33618

Title AMBR

BALLAS, JAMES
3411 Skysail Pl
Tampa, FL 33607




Detail by Entity Name
Florida Profit Corporation

LEGALINC CORPORATE SERVICES INC.

Filing Information
Document Number
P12000047957
FEI/EIN Number
45-3566742
Date Filed
05/23/2012
State
FL
Status
ACTIVE
Principal Address
10601 Clarence Dr.
Ste. 250
Frisco, TX 75033

Changed: 08/16/2017
Mailing Address
10601 Clarence Dr.
Ste. 250
Frisco, TX 75033

Changed: 08/16/2017
Registered Agent Name & Address
UNITED STATES CORPORATION AGENTS, INC.
5575 S. SEMORAN BLVD.
SUITE 36
ORLANDO,, FL 32822

Name Changed: 09/18/2019

Address Changed: 01/21/2020
Officer/Director Detail
Name & Address

Title President

Treutlein , Erik
10601 Clarence Dr.
Ste. 250
Frisco, FL 75033

Title Director

Treutlein, Erik
10601 Clarence Dr.
Ste. 250
Frisco, TX 75033

Title Director

Monestere, Frank
10601 Clarence Dr.
Ste. 250
Frisco, TX 75033

Title Director

Preece, Rich
10601 Clarence Dr.
Ste. 250
Frisco, TX 75033




Foreign Profit Corporation

UNITED STATES CORPORATION AGENTS, INC.

Filing Information
Document Number
F01000001626
FEI/EIN Number
95-2073977
Date Filed
03/26/2001
State
NV
Status
ACTIVE
Last Event
NAME CHANGE AMENDMENT
Event Date Filed
04/26/2006
Event Effective Date
NONE
Principal Address
5575 S. Semoran Blvd. Suite 36
Orlando, FL 32822

Changed: 06/14/2019
Mailing Address
101 N Brand Blvd
11th Floor
Glendale, CA 91203

Changed: 04/04/2018
Registered Agent Name & Address
NORTHWEST REGISTERED AGENT LLC.
7901 4TH STREET N,
SUITE 300
ST.PETERSBURG, FL 33702

Name Changed: 08/12/2010

Address Changed: 01/28/2019
Officer/Director Detail
Name & Address

Title CEO

Wernikoff , Dan
101 N BRAND BLVD 11TH FLOOR
GLENDALE, CA 91203

Title S, D

Miller , Nicole
101 N BRAND BLVD 11TH FLOOR
GLENDALE, CA 91203

Title CFO, D

Watson , Noel
101 N BRAND BLVD 11TH FLOOR
GLENDALE, CA 91203

Title D

Preece , Richard
101 N Brand Blvd
11th Floor
Glendale, CA 91203

AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
March 04 2021 - 06:50AM
GlobeNewswire Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.
AIM’s presentation will be available on-demand to registered attendees via the conference platform beginning Tuesday, March 9, 2021, at 7:00 AM Eastern Time. The webcast will be accessible here, and the presentation will be available on the investor relations section of AIM's website at https://aimimmuno.com/events-presentations/. Management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

Its an ever increasingly "small world after all".......

Tweet: Sipp Industries
@SippIndustries
Had a good meeting with Elite Beverage International yesterday to discuss distribution plans for #TequilaComisario and upcoming #BlueBearVodka. $SIPC


Pic of real people included

Had a good meeting with Elite Beverage International yesterday to discuss distribution plans for #TequilaComisario and upcoming #BlueBearVodka. $SIPC pic.twitter.com/olYzGhVtcU

— Sipp Industries (@SippIndustries) March 3, 2021

@wanderportcorp
We need more entries. Love to hear your creative answers.

https://twitter.com/wanderportcorp


@wanderportcorp
CRYPTO 9 CONTEST: Guess the inspiration behind the Crypto 9 token name and tag
@wanderportcorp
and
@crypto9coffee
. First 3 winners will each receive 1,000 Crypto 9. Contest ends March 15, 2021. $WDRP

#ethereum #ERC20 #crypto9token #crypto9coffee
9:52 AM · Mar 1, 2021·TweetDeck

Summit Wireless Technologies to Host Fourth Quarter Update Conference Call on March 12th
March 02 2021 - 04:05PM
Business Wire
Summit Wireless Technologies, Inc. (NASDAQ: WISA), a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems and founding member of the WiSA Association, announced management will hold a call to provide a business update including its fourth quarter results at 8:00 a.m. PT / 11:00 a.m. ET on Friday, March 12, 2021.

Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 877-423-9813 or 201-689-8573 and referencing code 13716790 approximately 10 minutes prior to the start time. To bypass the operator and receive a call rather than dialing in, please use the following link approximately 15 minutes prior to the call. A live webcast of the call and accompanying slide presentation will be on the investor relations section of the company’s website at ir.summitwireless.com and available for approximately one year. An audio archive can be accessed for one week by dialing 844-512-2921 or 412-317-6671 and entering conference ID 13716790.

About Summit Wireless Technologies, Inc.
Summit Wireless Technologies, Inc. (NASDAQ:WISA) is a leading provider of immersive, wireless sound technology for intelligent devices and next-generation home entertainment systems. Working with leading CE brands and manufacturers such as Harman International, a division of Samsung, LG Electronics, Klipsch, Bang & Olufsen, Xbox, a subsidiary of Microsoft, and others, Summit Wireless delivers seamless, dynamic audio experiences for high-definition content, including movies and video, music, sports, gaming/esports, and more. Summit Wireless is a founding member of WiSA, the Wireless Speaker and Audio Association and works in joint partnership to champion the most reliable interoperability standards across the audio industry. Summit Wireless is headquartered in San Jose, CA with sales teams in Taiwan, China, Japan, and Korea. For more information, please visit: www.summitwireless.com.

© 2020 Summit Wireless Technologies, Inc. All rights reserved. Summit Wireless Technologies and the Summit Wireless logo are trademarks of Summit Wireless Technologies, Inc.



View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005982/en/

Kirsten Chapman, LHA Investor Relations, +1 415-433-3777, summit@lhai.com

WDRP is just getting started. Retooling older aspects and adding new business. Health care products including CBD, Hemp coffee, New brand of coffee with a Crypto twist, plus there holdings of SIPC stock (25mill in 2017, 12.5 mill for the Elite Beverage shares and convertibles on loans to SIPC) Had or still have 60K of warrants for Elite Beverage. Should be an interesting year.

Maybe a material event about to happen? Nothing on https://otce.finra.org/otce/dailyList

Tweet: Sipp Industries
@SippIndustries
Exploring ways with #EliteBeverage today to expand #TequilaComisario market and distribution of #BlueBearVodka. #tequila #vodka #spirits
https://twitter.com/SippIndustries

TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact: Investor Contact:
Mark Wiggins Andrew McDonald
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 646-597-6987
mwiggins@traconpharma.com Andrew@lifesciadvisors.com

https://www.globenewswire.com/news-release/2021/03/02/2185292/0/en/TRACON-Pharmaceuticals-to-Present-at-the-H-C-Wainwright-Global-Life-Sciences-Conference.html

Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors
March 02 2021 - 08:30AM
GlobeNewswire Inc.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the election of Steven D. Skolsky to its Board of Directors.
Mr. Skolsky is a well-established senior executive with over 35 years of experience in healthcare and the life sciences in both private and public sectors. Over the course of his career, he has amassed expertise spanning all facets of the biopharmaceutical and healthcare services industry from research and early-stage discovery to product development and commercialization.

“Electing Steve to our board, a leader in the industry with a successful track record in commercialization, marketing strategy, and multiple successful product launches, is invaluable. As we quickly approach a targeted data readout in our pivotal Phase 3 B-SIMPLE4 study, it is important for us to start planning for success and the potential commercialization of SB206 for the treatment of molluscum. We look forward to leveraging Steve’s insights as we continue to advance the Company and build near and long-term shareholder value,” commented Paula Brown Stafford, President and Chief Executive Officer of Novan.

Mr. Skolsky currently serves as the founding Principal of Expis Partners, a strategic consulting firm to the biotech, pharmaceutical, life science and clinical services community, with a focused expertise in commercialization, marketing strategy, drug development, operations, strategic planning and corporate and business development. From 2011-2016, Mr. Skolsky held senior executive roles at Quintiles Transnational Holdings, Inc. (now IQVIA), most recently as Senior Vice President & Managing Director and previously, Senior Vice President and Head of Global Clinical Operations. Prior to joining Quintiles, he served as the President and Chief Executive Officer of Sequoia Pharmaceuticals Inc. and previously, Chief Executive Officer of Trimeris Inc. While at Trimeris, Mr. Skolsky expanded use and adoption of a novel HIV fusion inhibitor (Fuzeon®) to deliver a 10-fold increase in world-wide sales of $266M and ultimately transforming the business from a perennially loss making enterprise to one of sustained profitability.

Prior to that, Mr. Skolsky served for more than 20 years at GlaxoSmithKline plc (“GSK”) where he held a number of positions including senior leadership roles as Managing Director of GSK’s operations in Australia and New Zealand. As Senior Vice President, Global Product Strategy and Clinical Development at GSK, Mr. Skolsky was responsible for optimizing its clinical-commercial interface to deliver 59 product submissions and 42 regulatory approvals while developing launch platforms for 10 global product launches and increasing new product portfolio value by developing and implementing strategic clinical development plans, product line extension and life cycle management plans.

“I am excited to be joining Novan at this pivotal time for the Company. I believe they have the potential to address a significant unmet need in the treatment of molluscum contagiosum and I look forward to working closely with the management team as the Company advances towards potentially becoming a commercial-stage company,” added Mr. Skolsky.

In addition to joining the Novan Board, Mr. Skolsky serves on the Boards of Directors of Basilea Pharmaceutica, a Swiss-based biotech company, Clinipace Clinical Research, Elligo Health Research, The Foundation Board of University of North Carolina at Chapel Hill’s Kenan Flagler Business School, The Board of Visitors of UNC-Chapel Hill and The Lineberger Cancer Center. Mr. Skolsky holds a B.A. in Biology from UNC-Chapel Hill.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company’s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “target,” “anticipate,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on the Company’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements related to the potential therapeutic value of the Company’s NITRICIL™ platform technology, the Company’s pharmaceutical development of nitric oxide-releasing product candidates, the Company’s intention to advance development and potential commercialization of certain product candidates, including the timing and progress of our Phase 3 program to evaluate SB206 for the treatment of molluscum and the timing of anticipated topline results. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the Company’s expectations, including, but not limited to, any operational or other disruptions as a result of the COVID-19 pandemic, including any delays or disruptions to the conduct of the B-SIMPLE4 study; risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, potential for delays or other impacts, whether as a result of the COVID-19 pandemic or other factors, and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that the Company’s product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that the Company may not obtain funding sufficient to complete the regulatory or development process; the Company’s ability to obtain additional funding or enter into strategic or other business relationships necessary or useful for the further development and potential commercialization of the Company’s product candidates; the risk that disruptions at the FDA or other agencies could cause such agencies to cancel or postpone meetings or otherwise impact the ability of such agencies to provide regulatory guidance or feedback or timely review and process the Company’s regulatory submissions, all of which could have a material adverse effect on the Company’s business; risks related to the manufacture of raw materials, including the Company’s active pharmaceutical ingredient, and drug product components utilized in clinical trial materials, including failure to transfer technology and processes to third parties effectively or failure of those third parties to obtain approval of and maintain compliance with the FDA or comparable regulatory authorities; the Company’s reliance on arrangements with third parties to support its operations and development efforts and the risk that such parties will not successfully carry out their contractual duties or meet expected deadlines; the risk that the Company may not be successful in commercializing any product candidate that receives regulatory approval if the Company is unable to establish sales, marketing and distribution capabilities for that product candidate; and other risks and uncertainties described in the Company’s annual report filed with the SEC on Form 10-K for the twelve months ended December 31, 2020, and in the Company’s subsequent filings with the SEC. Such forward-looking statements speak only as of the date of this press release and Novan disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

INVESTOR AND MEDIA CONTACT:

Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com

Still active https://altmedcenters.com/

RBS0238 CLINICAL STRENGTH PEPTIDE COMPLEX
Brand: RISING BIOSCIENCES INC
Amazon.com

Wanderport
@wanderportcorp
Product availability and #crypto9 circulation coming soon. $WDRP

#ERC20 #Ethereum #crypto9token
https://twitter.com/wanderportcorp

Crypto 9 Coffee
@crypto9coffee
Had a slight delay with the #Crypto9coffee packaging. Moving to production now. Products should be available for purchase soon.

#coffee #coffeelover #crypto9token #healthyliving
https://twitter.com/crypto9coffee

Securities Counsel
Vic Devlaeminck PC
10013 N.E. Hazel Dell Avenue

Suite 317

Vancouver, WA 98685

Shows up on both SIPC and WDRP filing for bring them current.

Relates to PR: Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
December 21, 2020 at 9:00 AM EST

MORRISVILLE, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a Master Services Agreement (MSA) with Catalent, which will include support of chemistry, manufacturing and control (CMC) activities and development of an intranasal formulation of berdazimer sodium for use in the Company’s coronavirus (COVID-19) program.

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Catalent’s advanced formulation development and manufacturing spans a range of technologies, along with integrated downstream clinical development and commercial supply solutions.

“We are pleased to be working with Catalent, and to benefit from its expertise in drug development and manufacturing, which is of particular interest to us in our COVID-19 program. We look forward to advancing into preclinical IND-enabling studies and taking another step towards unlocking the potential of our proprietary nitric oxide-based medicines,” commented Paula Brown Stafford, President and Chief Executive Officer of Novan.

“This is a tremendous opportunity for Catalent and Novan,” added Jonathan Arnold, President of Oral & Specialty Delivery, Catalent. “We are proud to leverage Catalent’s broad knowledge and expertise in formulation and inhalation technologies to help address the pressing needs associated with the COVID-19 pandemic.”

Novan initiated in vitro assessments of its NITRICIL™ platform against the novel SARS-CoV-2 coronavirus, targeting the reduction of viral burden in differentiated normal human bronchial epithelial cells. The studies were conducted at the Institute for Antiviral Research at Utah State University, and these results demonstrated the first instance of an antiviral effect from a nitric oxide-based medicine in a 3-D tissue model that has similar structure to the human airway epithelium. The results from the in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated that berdazimer sodium reduced 90% of virus after repeat dosing, once daily.

Based on the scientific literature and data available to-date with berdazimer sodium and Novan’s product candidate SB206, Novan believes that nitric oxide may inhibit viral replication by disrupting protein function critical for viral replication and infection through generation of reactive intermediates.

“Following the initial positive in vitro results that we announced earlier, we believe berdazimer sodium has the potential to offer benefit in inhibiting the replication of SARS-CoV-2, the virus that causes COVID-19, and we look forward to further exploring its potential. The knowledge and experience in formulation that Catalent has to offer provides a key component as we execute on our development path forward for this important program,” commented Dr. Carri Geer, Chief Technology Officer of Novan.

Following the completion of preclinical studies, Novan is targeting filing a potential IND application with the U.S. Food and Drug Administration and, subject to obtaining additional funding, targets initiating human clinical trials in the second half of 2021.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company’s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.

Anyone else see this as NOVN connection to possible future production and distribution of Novan's Berdazimer Sodium for covid?

Catalent Completes Acquisition of Dry Powder Inhaler Spray Drying, Capsule Manufacturing, and Packaging Capabilities from Acorda Therapeutics

SOMERSET, N.J. – February 15, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced it has completed the acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a developer of therapies to restore function and improve the lives of people with neurological disorders. The acquisition complements Catalent’s status as a premier U.S.-based partner for companies across dry powder inhaled dose forms.

Under the terms of the agreement, Catalent has acquired Acorda Therapeutics’ 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, close to Boston Logan International Airport and the thriving biotechnology networks centered around Boston and Cambridge. The site operates best-in-class spray drying capacity, including GEA NIRO® PSD-1, PSD-4 and PSD-7 spray drying units, with the latter unit being the largest equipment of its kind in North America, and will provide Catalent with significant commercial-scale capacity for new customer programs. The facility will act as a global center of excellence within the Catalent network for spray-dried dispersion and dry powder encapsulation and packaging. Acorda Therapeutics’ current workforce at the facility has transitioned employment to Catalent.

Catalent has also entered into a long-term supply agreement with Acorda Therapeutics to continue commercial manufacture of INBRIJA® (levodopa inhalation powder) from the Chelsea facility. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson’s disease treated with regular carbidopa/levodopa medicine.

“Catalent is a premier partner to companies working on multiple forms of inhaled drug delivery, from early-stage development to commercial-scale supply,” said Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. “This acquisition complements our existing U.S.-based capabilities in metered-dose and nasal inhalation by adding an experienced team of people and a premier facility enabling us to provide customers with extended capabilities for commercial-scale filling and packaging of dry powder inhalers.”

The Chelsea site will complement and provide downstream capabilities to Catalent’s 180,000 square-foot inhalation development facility in Morrisville, Research Triangle Park, North Carolina, which includes development and manufacturing for metered dose inhalers, nasal sprays, and dry powder inhalers. The Morrisville site offers high-speed commercial-scale manufacturing as well as flexible fill lines for clinical-scale and small batch production.

NIRO® is a registered trademark of GEA Group.

ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs around 15,000 people, including approximately 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com

Anything close to the 50 day MA is my target if I am lucky. Currently at 6.26

Insiders buying! 9 Form 4's after hours!
https://ih.advfn.com/stock-market/NASDAQ/summit-wireless-technolo-WISA/news